MRI analysis offers new insight into vaccine-related lymphadenopathy in the general population
A new article published in Radiology offers an updated overview of presentations of COVID vaccine-related lymphadenopathy, this time as visualized on chest MRI scans.
To date, research related to reactive lymphadenopathy has focused primarily on cancer patients who are regularly staged and monitored by PET/CT or women undergoing breast cancer screening and/or imaging. by mammography and ultrasound. While these studies have helped shape current recommendations regarding the timing of imaging after COVID vaccination in these patients, there remains a lack of data regarding a more general population, the study authors suggested.
“The early 2021 recommendations are tentative, and more appropriate management strategies for vaccine-related lymphadenopathy are needed both in the general population and in high-risk oncology patients,” corresponding author of the article Takeharu Yoshikawa, from the Department of Computational Diagnostic Radiology and Preventive Medicine at the University of Tokyo Hospital, and his colleagues wrote .
This study aimed to add to the conversation with data that includes both men and women – 300 men and 133 women, to be exact – of varying ages. Pre- and post-vaccination chest MRIs were obtained for each patient from June to October 2021. Various measures were compared between the two scans, including imaging characteristics and other patient health data (time of vaccination, age, etc.).